ASTELLAS , TAKEDA – ASCO-GU 2013 Review: Prostate Cancer – Xtandi Confirms Its Superiority In Early Setting, ARN-509 Is Emerging Threat To Xtandi, While TAK-700 Lags Behind!

Date: 2015-07

Clinical data presented at ASCO-GU 2013 confirms Xtandi (Enzalutamide, Astellas/Medivation) to be the next standard of care antiandrogen therapy across the treatment progression of prostate cancer amongst new treatment options (Zytiga, Provenge, Jevtana). Xtandi’s safety profile, its reported PhII data in hormone naïve setting at ASCO GU, and under increasing dilemma for using steroid for the treatment of mCRPC, brings Xtandi ahead in competition against Zytiga. We expect Xtandi to demonstrate better efficacy in the PhIII PREVAIL study (2H 2013, Prechemo, Zytiga OS-5.2 months) and TERRIAN study (against Casodex). While the pipeline of antiandrogen drugs is quite crowded (Table 1)……

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample